Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Syneos Health Showcases Evolved Deployment Solutions at Future Pharma in Boston

Syneos Health showcased Syneos Health Deployment Solutions at the Future Pharma Conference in Boston. Advancing the traditional outsourced field sales model, Deployment Solutions delivers a customized, integrated mix of promotional and educational channels purposefully designed to ensure successful commercialization.

Read More »

Lilly’s targeted RET drug shrinks tumors in lung cancer trial

Eli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.

Read More »

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.

Read More »

Healthline Announces Chronicon, a Live Event to Support People Living with Chronic Conditions

Healthline Media partners with wellness advocate Nitika Chopra to create Chronicon, bringing together hundreds of influencers to first daylong event devoted to people struggling with chronic health issues.

Read More »

Thrive or die in the omnichannel era

Norm Phillips, EVP and Chief Marketing Officer with BioPharm Communications, explains the challenges and opportunities for pharma and describes advantages they have compared to those in the consumer marketing world, such as identifiable influencers, customer-level data and access/reimbursement insights.

Read More »

Boehringer Ingelheim Lands Positive Results in Lung Disease Trial

Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.

Read More »

Merck’s Keytruda Cuts Death Risk by 31 Percent in Esophageal Cancer

Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.

Read More »

Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations

Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.

Read More »

These Seven Biotech Ideas Will Be Conversation Drivers for 2019

The online publication NEO.LIFE pointed to seven areas where biotech companies and researchers have significant potential to “dramatically reshape our concept of what it means to be human.”

Read More »

FDA approves Amneal’s generic dementia patch

The U.S. FDA approved Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom